Before You Join a Clinical Trial: Screening, Informed Consent, and Red Flags
You found a trial that looks right. Maybe your doctor suggested it, maybe you found it yourself. Either way, the moment between "this could help" and the first dose or session is not a formality. It is a structured process designed to protect you, and it works best when you understand it.
This guide covers that process for any condition: what screening involves, what the consent form must tell you, the questions worth asking, the fears almost everyone has, who is behind a trial and who is watching, and the red flags that should make you walk away.
What happens before you join: screening
Finding a promising trial is only the beginning. Next comes screening, a series of questions and tests that confirm you meet the study's eligibility criteria.
Before you reach that official step, TrialFinder has a quick eligibility check on each trial page. It is a first pass, not a substitute for the research team's screening, but it can help you see whether the basic criteria look like a fit.
The research team may ask about your diagnosis, symptoms, medications, previous treatments, other medical conditions, hospitalizations, and family medical history. Depending on the study, screening may also include blood tests, imaging, an ECG, a physical exam, or a detailed interview with a specialist.
Some of these questions can feel personal. You are allowed to ask why the information is needed, who will see it, and how it will be stored.
Screening protects you as much as it protects the study. A "no" at this stage usually means the treatment was not designed, or has not been proven safe, for someone with your specific profile. It is not a judgment about how sick you are or how much you deserve help.
The informed consent form: what it must explain
Before you join, you will receive an informed consent form. This is not a signature for the sake of bureaucracy. It is the document that tells you what you are agreeing to, and it should explain, in plain language:
What the study is testing, and why
What will happen at each visit
Which parts are experimental and which are standard care
Known and possible risks and side effects
Whether a placebo or comparison treatment is used, and what that means in practice
What happens if your condition gets worse during the study
What costs are covered and what is not
Whether travel or time is reimbursed
How your medical information will be used and protected
Who to contact with questions or urgent concerns
Your right to leave the study at any time, for any reason, without losing your regular care
Consent is not a test, and it is not a promise to finish the study. Take the form home if the study allows it. Read it with someone you trust. Ask the team to explain anything that does not make sense. A good research team will welcome the questions.
One more layer of protection worth knowing about: every legitimate trial is reviewed and approved by an independent ethics committee before it begins - an Institutional Review Board (IRB) in the US, an ethics committee in Europe, and an equivalent body in other countries. This committee is not part of the research team. Its job is to check that the protocol is safe and fair, and that the consent form tells you the truth. If a study cannot tell you which ethics committee approved it, that alone is a reason to walk away.
The most important questions to ask
You do not need a medical degree to interview a research team. Start with these:
What treatment might I actually receive? Ask about every study group, including placebo, standard care, or a comparison treatment, and how participants are assigned to groups.
Will my current treatment change? If the study asks you to stop, pause, or adjust a medication or treatment, ask who supervises the change, how it happens, and what the plan is if you feel worse.
What are the known risks? Ask about common side effects, rare serious risks, and any risk specific to the treatment being studied.
What happens if I get worse? There should be a clear plan. Ask whether support is available after hours, who decides whether you should stop, and how the team coordinates with your regular doctor.
Does the research team replace my regular doctor? In most studies, it does not. Ask how the two will share information.
How much time will this take? Ask about visit length and frequency, travel, remote check-ins, diaries or questionnaires, follow-up after treatment ends, and whether someone needs to come with you.
What will I have to pay? The study treatment and research-only tests are often covered by the sponsor, but routine medical care, transport, or time off work may not be. Ask what is paid for and what is not.
What happens when the study ends? Can you continue the treatment if it helped? Will the team help you transition back to ordinary care? Will they tell you which group you were in, and share the results?
Who can see my information? Ask how your medical notes, test results, samples, and any app or device data will be protected, and whether de-identified data may be used in future research.
Write the answers down. The right trial should still make sense after the excitement of finding it wears off.
Common fears, answered plainly
"Am I being used as a guinea pig?"
No one can promise that an experimental treatment will work. That uncertainty is the reason the trial exists. But a legitimate study must explain the risks, follow an approved protocol, monitor participants closely, and let you leave. You are a volunteer with rights, not a test subject without a voice.
"Will joining go on my record? Will people find out?"
Your participation is private medical information, but privacy is not the same as invisibility. Ask exactly what goes into your medical record, what is sent to your regular doctor, and who can access study data. The rules can vary by study and by country.
"What if I am put on placebo and nobody helps me?"
Do not settle for a vague answer. Ask what support every group receives, how often you will be checked, and what triggers urgent help or removal from the study. If the answer does not make you feel safe, pause.
"What if I get worse after I start?"
Tell the team early. Getting worse is not a failure, and it should never be hidden to avoid disappointing the researchers. A responsible study has a safety plan, including a way to assess urgent problems and connect you with care. And if you are ever in immediate danger, contact local emergency services. Do not wait for a research appointment.
"Does joining a trial mean I have run out of options?"
No. A clinical trial is not automatically a last resort. Some people join after standard treatments have not worked. Others join because a study tests a treatment with fewer side effects, a more convenient schedule, or an approach aimed at their specific situation. The question is not whether a trial is "desperate." The question is whether this particular trial is a reasonable option for you.
Who is behind a trial, and who is watching
Many people feel uneasy about clinical trials, and often for fair reasons. Some of the questions below come up in almost every family. Here are plain answers, and what you can check yourself.
"Is this just about a drug company making money?"
Often a company does fund the study. That is how most new drugs are developed, and the company usually hopes to sell the drug if it works. It is reasonable to know that.
What matters is that the company does not run the study alone. Before a study can start, an independent ethics committee has to review the protocol and the consent form. In the US this is called an Institutional Review Board (IRB), and it has the authority to approve a study, require changes, or reject it (FDA). The same kind of independent review exists in other countries, described below.
The sponsor also often pays for the costs of research itself, such as the study drug and tests done only for the study. The National Cancer Institute (NCI) says that many costs are covered by the sponsor, and that you should ask the study coordinator which costs are covered and which are not (NCI). Ask this in writing before you sign.
"Who checks the trial?"
In the US, an Institutional Review Board (IRB) reviews the protocol and the consent form before a study can start. It can approve a study, require changes, or reject it. For many drug studies, the Food and Drug Administration (FDA) is involved as well (FDA).
In Europe, an independent ethics committee reviews the study, and a national medicines regulator oversees it. For many studies that run in more than one EU country, the European Medicines Agency (EMA) is part of that picture too (EMA).
Every country has its own regulator. A legitimate study lists its approvals. Ask the study coordinator which committee approved the study at this site, and who to call with questions about your rights.
Before you join, you have to receive an explanation from the medical team and sign an informed consent form. That is a legal step, and it is yours to take slowly. Ask for the form to take home.
"How can I check a trial myself?"
You do not have to take anyone's word for it.
Look it up in a public registry. Many trials are listed on ClinicalTrials.gov, run by the US National Library of Medicine. The study sponsor or investigator submits the information and is responsible for its accuracy. The record shows the purpose, the groups, the sites, and, for many completed studies, posted results with side effects. A listing is not an endorsement by the US government, so use it to check facts, not as a stamp of approval.
Ask for the approval. Ask the study coordinator which ethics committee approved the study at this hospital, and who to call with questions about your rights.
Ask who your regular oncologist will hear from. You can often continue to see your current care team while in a study, and the NCI suggests asking how the study team will keep your oncologist informed (NCI).
"Not approved yet. Doesn't that mean not safe?"
"Not approved" means the evidence is still being collected. It does not mean nobody looked. A new treatment is first tested in the lab under controlled conditions, and a study in people starts only when those results look promising. Studies in people are a required step before a drug or technology can be approved for general use. Phase 1 is where safety and dose are checked first, in a small group.
It is also true that an experimental drug can have side effects nobody knows yet, and the NCI says so directly (NCI). Approval by a committee lowers the risk. It does not remove it. That is why the consent form and the questions above matter.
If someone in the family is against it
It is common for one person, a spouse, a parent, an adult child, to say "don't be a guinea pig." They usually mean "I'm afraid for you." It can help to bring them to the conversation with the doctor or the study coordinator and let them ask their own questions. Questions that tend to help:
What exactly is being tested, and what do we know so far?
What is the alternative if we do not join?
Which committee approved it, and what are the risks listed in the consent form?
What happens if the patient wants to stop?
The decision is the patient's. A trial is voluntary, and the patient can stop at any time and go back to standard care.
Red flags that should make you pause
Be cautious if someone:
Promises a cure, or guarantees that you will receive the experimental treatment
Pressures you to sign immediately
Tells you to change or stop your current treatment without a supervised plan
Cannot clearly explain placebo, comparison groups, or randomization
Avoids questions about side effects, risks, or emergency support
Asks you to pay a large amount simply to access an experimental treatment
Will not give you a consent form or contact details for the study team
A real trial should be searchable in a recognized trial registry and should clearly identify the sponsor, study sites, eligibility criteria, and contact information. Registration alone does not prove that a trial is right for you, but missing basic information is a reason to slow down.
Take your time
A diagnosis can make decisions feel urgent. Families may also feel pressure to find the next answer quickly. But urgency should not take away your right to understand what you are agreeing to.
Ask questions. Read the consent form. Involve someone you trust. Talk to the doctor who already knows you. And remember that saying no to one study does not mean saying no to research forever.
The right trial is not simply one you can enter. It is one whose possible benefits, risks, time commitment, and safety plan you understand well enough to choose freely.
FAQ
Am I being used as a guinea pig?
No one can promise that an experimental treatment will work. That uncertainty is the reason the trial exists. A legitimate study must explain the risks, follow an approved protocol, monitor participants closely, and let you leave. You are a volunteer with rights, not a test subject without a voice.
Will joining a clinical trial go on my record?
Your participation is private medical information, but privacy is not the same as invisibility. Ask exactly what goes into your medical record, what is sent to your regular doctor, and who can access study data. The rules can vary by study and by country.
What if I am put on placebo and nobody helps me?
Do not settle for a vague answer. Ask what support every group receives, how often you will be checked, and what triggers urgent help or removal from the study. If the answer does not make you feel safe, pause.
What if I get worse after I start a clinical trial?
Tell the team early. Getting worse is not a failure, and it should never be hidden to avoid disappointing the researchers. A responsible study has a safety plan, including a way to assess urgent problems and connect you with care. If you are ever in immediate danger, contact local emergency services.
Does joining a trial mean I have run out of options?
No. A clinical trial is not automatically a last resort. Some people join after standard treatments have not worked. Others join because a study tests a treatment with fewer side effects, a more convenient schedule, or an approach aimed at their specific situation.
Is this just about a drug company making money?
Often a company does fund the study. That is how most new drugs are developed. The company does not run the study alone: an independent ethics committee has to review the protocol and the consent form first. In the US this is an Institutional Review Board (IRB). In Europe it is an ethics committee, with a national regulator or the EMA involved as well.
Who checks the trial?
In the US, an IRB reviews the protocol and the consent form, and the FDA is involved in many drug studies. In Europe, an ethics committee reviews the study and a national regulator oversees it, with the EMA involved in many multi-country studies. Every country has its own regulator. A legitimate study lists its approvals.
Not approved yet. Doesn't that mean not safe?
Not approved means the evidence is still being collected. It does not mean nobody looked. A study in people starts only after lab results look promising. Committee approval lowers the risk. It does not remove it. That is why the consent form and your questions matter.
How to Talk to Your Doctor About Clinical TrialsWhat questions should you ask your doctor about clinical trials? A step-by-step guide for patients: when to bring it up, what to prepare, and what to do after.
Key Clinical Trial TermsPlain-language explanations of terms patients and families encounter during the clinical trial process.
This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.